Vivek Subbiah: We’ve been to the moon, now we need to go to Mars and beyond to eradicate cancer
Vivek Subbiah, posted the following on Twitter:
What is the best way to spend that extra hour from Daylight Saving Time ? Spectacular discussions with my GU band of brothers Neeraj Agarwal, Toni Choueiri, Sumanta K. Pal about how can we help train the next generation oncologists in clinical trials & help more patients. Winning Team Fearsome Four to eradicate cancer
Just back in time from Society for Immunotherapy of Cancer 2023 to meet with best friends visiting nashville for Uromigos Live.
We’ve been to the moon, now we need to go to Mars & beyond to eradicate cancer.”
Source: Vivek Subbiah/Twitter
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023